Spero Therapeutics, Inc. (SPRO)
2.79
+0.03
(+1.09%)
USD |
NASDAQ |
May 15, 16:00
2.795
0.00 (0.00%)
Pre-Market: 20:00
Spero Therapeutics Enterprise Value : 107.89M for May 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 1.211B |
| Lantern Pharma, Inc. | 29.08M |
| ACADIA Pharmaceuticals, Inc. | 2.864B |
| Alnylam Pharmaceuticals, Inc. | 38.28B |
| Amgen, Inc. | 221.49B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.203M |
| Revenue (Quarterly) | 0.258M |
| Total Expenses (Quarterly) | 7.461M |
| EPS Diluted (Quarterly) | -0.1258 |
| Profit Margin (Quarterly) | -2.79K% |
| Earnings Yield | 8.73% |
| Operating Earnings Yield | 4.86% |
| Normalized Earnings Yield | 9.032 |